These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34986655)

  • 1. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
    Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
    Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
    Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
    Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
    Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
    Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
    Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
    Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
    Zhang SL; Han CB; Sun L; Huang LT; Ma JT
    Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endostar improved efficacy of concurrent chemoradiotherapy with vinorelbine plus carboplatin in locally advanced lung squamous cell carcinoma patients with high serum Lp(a) concentration.
    Xu H; Lv D; Meng Y; Wang M; Wang W; Zhou C; Zhou S; Chen X; Yang H
    Ann Palliat Med; 2020 Mar; 9(2):298-307. PubMed ID: 32075401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
    Zhang J; Lv PY; Zhao X; Liu ML; Qiu LP; Yang ZZ; Sun SJ; Zhang GQ
    BMC Cancer; 2024 Aug; 24(1):967. PubMed ID: 39112947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Yuan M; Zhai Y; Men Y; Wang J; Deng L; Wang W; Bao Y; Yang X; Sun S; Ma Z; Liu Y; Wang J; Zhu H; Hui Z
    Thorac Cancer; 2021 Dec; 12(23):3208-3215. PubMed ID: 34676669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endostatin combined with platinum-based chemo-radiotherapy for advanced non-small cell lung cancer.
    Jiang X; Guan W; Li M; Liang W; Qing Y; Dai N; Zhang S; Deng Y; Meng H; Yang Y; Zhong Z
    Cell Biochem Biophys; 2015 Mar; 71(2):571-7. PubMed ID: 25209742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
    BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)].
    Han BH; Xiu QY; Wang HM; Shen J; Gu AQ; Luo Y; Bai CX; Guo SL; Liu WC; Zhuang ZX; Zhang Y; Zhao YZ; Jiang LY; Shi CL; Jin B; Zhou JY; Jin XQ
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):854-9. PubMed ID: 22335953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical Observation of Recombinant Human Vascular Endostatin Durative Transfusion Combined with Window Period Arterial Infusion Chemotherapy in the Treatment of 
Advanced Lung Squamous Carcinoma].
    Lv Y; Jiang R; Ma C; Li J; Wang B; Sun L; Mu N
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):500-4. PubMed ID: 26302347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
    Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
    Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
    Chen L; Tong F; Peng L; Huang Y; Yin P; Feng Y; Cheng S; Wang J; Dong X
    Radiother Oncol; 2022 Sep; 174():44-51. PubMed ID: 35788355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
    Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
    Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
    Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
    Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
    Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
    Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
    Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
    Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.